KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
Beginning on March 6, 2017, members of the management team of
Kura Oncology, Inc. (the Company) will be providing presentation
materials (the Presentation) to certain interested parties.A copy
of the Presentation is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
The information contained in this Current Report on Form 8-K and
in the accompanying Exhibit 99.1 are being furnished and shall
not be deemed to be filed for the purposes of Section 18 of the
Securities and Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section and will not be
incorporated by reference into any registration statement filed
by the Company, under the Securities Act of 1933, as amended,
unless specifically identified as being incorporated therein by
reference. This Current Report on Form 8-K will not be deemed an
admission as to the materiality of any information in this
Current Report on Form 8-K that is being disclosed to Regulation
FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Presentation Materials of Kura Oncology, Inc. |
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. KURA ONCOLOGY, INC. (NASDAQ:KURA) Recent Trading Information
KURA ONCOLOGY, INC. (NASDAQ:KURA) closed its last trading session down -2.70 at 7.30 with shares trading hands.
